1-3 of 3
Martin M Oken, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008

Chezi Ganzel, MD, Judith Manola, MS, Dan Douer, MD, Jacob M. Rowe, MD, Hugo F Fernandez, MD, Elisabeth Paietta, Ph.D, Mark R. Litzow, MD, Ju-Whei Lee, Selina M Luger, MD, Hillard M. Lazarus, MD, Larry Cripe, MD, Martin M Oken, MD, Peter A Cassileth, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2013) 122 (21): 63.
https://doi.org/10.1182/blood.V122.21.63.63
Published: 2013
Journal Articles

Oral Antibiotic Prophylaxis of Early Infection In Multiple Myeloma: A URCC/ECOG Phase III Study

David H. Vesole, MD, PhD, Martin M Oken, MD, Charles Heckler, Philip R. Greipp, MD, Michael S Katz, BS., MBA, Susanna Jacobus, MS, Gary R Morrow, PhD, MS, On Behalf of the University of Rochester Cancer Center and the Eastern Cooperative Oncology Group
Journal: Blood
Blood (2010) 116 (21): 3017.
https://doi.org/10.1182/blood.V116.21.3017.3017
Published: 2010
Journal Articles

Prognostic Value of Syndecan-1 in Multiple Myeloma and its Relationship with Other Prognostic Factors.

Shaji Kumar, MD, Emily Blood, Martin M. Oken, MD, Philip R. Greipp, MD
Journal: Blood
Blood (2004) 104 (11): 2402.
https://doi.org/10.1182/blood.V104.11.2402.2402
Published: 2004